Table 5 Best response during treatment

From: Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

Overall response a

No. of patients

% of patients ( N =27)

Partial response (PR)

8

30

Stable disease (SD)

12

44

Progressive disease (PD)

6

22

Not evaluable (NE)

1

4

  1. aPR; at least 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter.
  2. SD; neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum longest diameter since the treatment started.
  3. PD; at least a 20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started or the appearance of new lesions.
Back to article page